Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. Read More The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA. The listed name for VRCA is Verrica Pharmaceuticals Inc. Common Stock.